

RESEARCH ARTICLE

Open Access

Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in *KCNH2*

Michael Christiansen^{1*}, Paula L Hedley^{1,2†}, Juliane Theilade^{3†}, Birgitte Stoevring¹, Trond P Leren⁴, Ole Eschen⁵, Karina M Sørensen¹, Anne Tybjærg-Hansen⁶, Lilian B Ousager⁷, Lisbeth N Pedersen⁸, Ruth Frikke-Schmidt⁶, Frederik H Aidt¹, Michael G Hansen⁹, Jim Hansen¹⁰, Poul E Bloch Thomsen¹⁰, Egon Toft¹¹, Finn L Henriksen¹², Henning Bundgaard³, Henrik K Jensen¹³ and Jørgen K Kanters^{9,14,15}

Abstract

Background: Long QT syndrome (LQTS) is a cardiac ion channelopathy which presents clinically with palpitations, syncope or sudden death. More than 700 LQTS-causing mutations have been identified in 13 genes, all of which encode proteins involved in the execution of the cardiac action potential. The most frequently affected genes, covering > 90% of cases, are *KCNQ1*, *KCNH2* and *SCN5A*.

Methods: We describe 64 different mutations in 70 unrelated Danish families using a routine five-gene screen, comprising *KCNQ1*, *KCNH2* and *SCN5A* as well as *KCNE1* and *KCNE2*.

Results: Twenty-two mutations were found in *KCNQ1*, 28 in *KCNH2*, 9 in *SCN5A*, 3 in *KCNE1* and 2 in *KCNE2*. Twenty-six of these have only been described in the Danish population and 18 are novel. One double heterozygote (1.4% of families) was found. A founder mutation, p.F29L in *KCNH2*, was identified in 5 “unrelated” families. Disease association, in 31.2% of cases, was based on the type of mutation identified (nonsense, insertion/deletion, frameshift or splice-site). Functional data was available for 22.7% of the missense mutations. None of the mutations were found in 364 Danish alleles and only three, all functionally characterised, were recorded in the Exome Variation Server, albeit at a frequency of < 1:1000.

Conclusion: The genetic etiology of LQTS in Denmark is similar to that found in other populations. A large founder family with p.F29L in *KCNH2* was identified. In 48.4% of the mutations disease causation was based on mutation type or functional analysis.

Background

Long QT syndrome (LQTS) is a genetic disease of the cardiac electrical system which presents clinically with palpitations, syncope and sudden death [1,2]. To date, more than 700 disease-causing mutations have been found in 13 genes [1-3] and the total number of mutations is probably larger [4]. All these genes are directly or indirectly involved in the execution of the cardiac action potential (AP) [2]. LQTS is a consequence of a prolongation of the repolarisation phase of the AP,

caused by decreased activity of the repolarising inward K^+ -currents, I_{ks} and I_{kr} , or increased late activity of the outward depolarising Na^+ -current, I_{Na} . The delayed repolarisation leads to the appearance of early after depolarisations (EADs), due to enhancement of the Na^+/Ca^{2+} -exchanger and the L-type Ca^{2+} channel [5]. These, together with increased refractoriness, may trigger malignant arrhythmias [2].

In Denmark, genetic diagnostics of LQTS has been performed since 1996. From 2006 the management of LQTS patients has followed national guidelines [6]. The genetic diagnostic work is centred in five University cardiology clinics and patients are offered a five-gene screen of the most frequently affected genes, *KCNQ1*, *KCNH2*,

* Correspondence: mic@ssi.dk

†Equal contributors

¹Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Ørestads Boulevard 5, 2300S, Copenhagen, Denmark
Full list of author information is available at the end of the article

SCN5A, *KCNE1* and *KCNE2*. Initially, the screen was performed using single strand conformation polymorphism analysis (SSCP) of the coding regions of the genes with intronic amplification primers [7-9]. In recent years, the mutation analysis has been performed by bi-directional Sanger sequencing of coding regions and all previous patients have been reanalysed. Here we report the disease-causing mutations identified in Danish LQTS families during the preceding 15 years. Furthermore, as the evidence base for considering mutations disease-causing is not always clear [10], and rare variants which are not associated with disease are found in controls [11], we report our reasoning for considering the variants found in this cohort disease-causing. Finally, we compare the distribution of mutations with that found in other population studies.

Methods

Patients

The patients were 70 Danish LQTS probands from unrelated families where mutation screening in the five LQTS associated genes *KCNQ1*, *KCNH2*, *KCNE1*, *KCNE2* and *SCN5A* had led to the identification of a disease-causing mutation. LQT diagnosis was based on the clinical examination of patients, which was performed according to guidelines issued by the Danish Cardiology Society [6] by specialists in cardiology from Danish cardiology departments at Rigshospitalet, Skejby Hospital, Aalborg Hospital, Gentofte Hospital, Haderslev Hospital and Odense Hospital. All patients had a QT_C interval > 440 ms for men and 450 ms for women. All patients were Caucasian. A clinical description of patients identified through a Danish nationwide survey comprising 59 families (all contributing to the current survey) has recently been published [12].

Mutation identification

Genomic DNA was extracted from EDTA-blood using the commercially available Maxwell™ 16 Blood DNA purification kit on the Maxwell^R 16 System (Promega Biotech AB, Nacka, Sweden). Genetic screening was performed by bi-directional sequencing of PCR amplified exons with associated flanking intronic regions. Primers sequences are available on request. A minor proportion of mutations were identified at genetic departments at Skejby University Hospital, Rigshospitalet as well as in Norway and the Netherlands using other, but similar, technologies. All probands had the coding regions of the five genes sequenced. All mutations were verified by sequencing a second amplified amplicon. A large proportion of patients were examined for large deletions in *KCNQ1*, *KCNH2*, *KCNE1*, *KCNE2* and a small part of *SCN5A* by multiplex-ligation-dependent amplification (MLPA) using the SALSA MLPA P114 kit (MRC-Holland, Amsterdam, The Netherlands).

Mutation and protein nomenclature

Mutation nomenclature uses numbering with the A of the initiation codon ATG as +1 (www.hgvs.org/mutnomen), based on the following RefSeqs: NM_000218.2 (*KCNQ1*), NM_000238.2 (*KCNH2*), NM_000335.4 (*SCN5A*), NM_000219.3 (*KCNE1*) and NM_172201.1 (*KCNE2*). All mutations were checked using Mutalyzer. The protein nomenclature was that used in the recent mutation update on LQTS [2].

Evaluation of sequence changes

Deletions, frameshift-, splice- and nonsense mutations were considered disease-causing if not found in controls. Concerning missense mutations, familial segregation was ascertained if possible, but nuclear family size was in all cases so small that it precluded a proper linkage analysis [12]. Instead it was ascertained that the family did not contain affected members that did not carry the family mutation. Conservation of residues across several species was examined. All genetic variants were evaluated in 182 randomly and anonymously collected blood donor controls (364 alleles). The frequency of identified variants was assessed using the Exome Variant Server (EVS) v.0.0.21. (<http://evs.gs.washington.edu>). It was established whether genetic variants had previously been associated with LQTS and whether functional analysis had been performed. The potential functional effect of changes in amino acid composition was assessed *in silico* using the prediction servers Polyphen-2 (<http://genetics.bwh.harvard.edu/pph2/>) [13], SIFT (<http://sift.bii.a-star.edu.sg>) [14], and MutationAssessor (<http://www.ngl.org.uk/Manchester/page/mutation-assessor>) [15]

Haplotyping *KCNH2*

Haplotyping was performed using the microsatellites D7S1824, D7S1826 up-stream of *KCNH2* and D7S636, D7S3070, D7S483 and D7S1807 downstream of *KCNH2* (Figure 1). CentiMorgan distances were obtained from the Map-O-Mat database for microsatellites (<http://compgen.rutgers.edu/Mapomat/>). PCR amplicons were generated using fluorescently end-labelled primers (available at NCBI UniSTS) at 0.4 μM per primer, per reaction. A loading mix




Figure 1 Location of microsatellite markers used in haplotyping the p.F29L and p.K101E mutations in *KCNH2*.

of 0.5 µl amplicon, 9 µl HiDi formamide (Applied Biosystems, Foster City, CA, USA) and 0.5 µl 600LIZ size standard (Applied Biosystems) was prepared, and DNA products were electrophoresed on an ABI PRISM® 3100 Genetic Analyser. Data were analysed using ABI GeneMapper software v4.0 (Applied Biosystems).

Results

Mutation screening

The results of the mutation screening are summarized in Tables 1, 2, 3. In the 70 families we found 64 different mutations; 22 in *KCNQ1*, 28 in *KCNH2*, 9 in *SCN5A*, 3 in *KCNE1* and 2 in *KCNE2*. All patients were heterozygous carriers of a single mutation, except one double heterozygous proband (1.4% of families), who carried p.R583G in *KCNQ1* and p.A93T in *KCNE1*. Twenty-six of the mutations have only been described in Danish LQTS patients (Tables 1, 2, 3), 18 have not been reported previously. Two mutations in *KCNH2*, p.F29L and p.K101E were found in 5 and 2 unrelated families, respectively. The MLPA analysis, applied to 65 of the probands, resulted in the identification of a single three exon (7-9) deletion,

IVS6_IVS10del, in *KCNQ1*. None of the mutations were found in 384 control alleles.

KCNQ1 mutations

The twenty-two mutations identified in *KCNQ1* seemed evenly spread out over the gene (Table 1). Only three of the mutations (p.F157C, IVS6_IVS10del and p.R583G) had not previously been described in other populations. The IVS6_IVS10del results, theoretically, either in the excision of a considerable part of the protein rendering it non-functional or in haploinsufficiency due to mRNA surveillance mechanisms [62], and is thus considered pathogenic. The remaining missense mutations all affect highly conserved residues and many missense mutations have been described in the S2-S3 and C-terminal regions of the protein, respectively [2]. The p.R583G affects a codon, where another missense mutation, p.R583C, has been shown to have an electrophysiological phenotype similar to that expected for a LQTS-associated mutation [42]. Among the 18 mutations previously seen in other populations, there were two frameshift mutations, two deletions, one splice-site mutation and one nonsense mutation. All of

Table 1 Mutations identified in *KCNQ1*

Gene	cDNA	Protein	Mutation type	Genomic region	Protein region	Phenotype	References
<i>KCNQ1</i>	NM_000218	NP_000209					
	c.217C > A	p.P73T	Missense	Exon_01	N-term	RWS	[4,16]
	DK c.470T > G	p.F157C	Missense	Exon_02	S2	RWS	[17]
	c.572-576del	p.L191fs	Frameshift	Exon_03	S2-S3	RWS	[4,18]
	c.592A > G	p.I198V	Missense	Exon_03	S2-S3	RWS	[4]
	c.674C > T	p.S225L	Missense	Exon_04	S3-S4	RWS	[4,19]
	c.667C > T	p.A226V	Missense	Exon_04	S3-S4	RWS	[4,20]
	c.760G > A*	p.V254M	Missense	Exon_05	S4-S5	RWS	[4,20-26]
	c.817C > T*	p.L273F	Missense	Exon_06	S5	RWS	[4,20,21,25-28]
	c.905C > T	p.A302V	Missense	Exon_06	Pore	RWS	[4,22]
	c.944A > G*	p.Y315C	Missense	Exon_07	Pore	RWS	[4,19,20,22,29-31]
	c.1015-1017del	p.F339del	Deletion	Exon_07	S6	RWS	[32]
	DK IVS6_IVS10del	Unknown	Deletion	Exon_07-Exon_9	Unknown	RWS	This study
	c.1017-1019del	p.F340del	Deletion	Exon_07	S6	RWS	[4,20,25,33]
c.1032G > A	p.A344sp	Splice-site	IVS_07	C-term	RWS	[4,22,25,26,34-37]	
c.1048G > A	p.G350R	Missense	Exon_08	C-term	RWS	[4,38]	
DK c.1087C > A	p.H363N	Missense	Exon_08	C-term	RWS	[2,26]	
c.1096C > T	p.R366W	Missense	Exon_08	C-term	RWS	[4,9,22,26,31]	
c.1202insC	p.P400fs	Frameshift	Exon_09	C-term	RWS	[4,20,39]	
c.1588C > T*	p.Q530X	Nonsense	Exon_12	C-term	RWS	[4,20,25,28,40,41]	
c.1747C > T*	p.R583C	Missense	Exon_15	C-term	RWS	[25,42]	
DK c.1747C > G	p.R583G	Missense	Exon_15	C-term	RWS	This study	
c.1748G > A	p.R583H	Missense	Exon_15	C-term	RWS	[38]	

DK: Only seen in patients of Danish origin. **in vitro* functional characterisation performed. RWS: Romano-Ward syndrome.

Table 2 Mutations identified in *KCNH2*

Gene	cDNA	Protein	Mutation type	Genomic region	Protein region	Phenotype	References
<i>KCNH2</i>	NM_000238	NP_000229					
DK	c.65T > C	p.F22S	Missense	Exon_01	N-term	RWS	This study
	c.87C > A*	p.F29L	Missense	Exon_01	N-term	RWS	[4,26,43]
DK	c.88-90del	p.I30del	Deletion	Exon_01	N-term	RWS	This study
	c.221C > T	p.T74M	Missense	Exon_02	PAS	RWS	[4,38]
DK	c.234_241dupTGCCGCGC	p.A83fs	Frameshift	Exon_02	PAS	RWS	This study
DK	c.287T > C	p.I96T	Missense	Exon_02	PAS	RWS	[8]
DK	c.301A > G	p.K101E	Missense	Exon_02	PAS	RWS	[8,44]
DK	c.326T > C	p.L109P	Missense	Exon_03	PAS	RWS	This study
DK	c.446insC	p.R148fs	Frameshift	Exon_03	N-term	RWS	This study
	c.453delC	p.P151fs	Frameshift	Exon_03	N-term	RWS	[45]
	c.526C > T	p.R176W	Missense	Exon_04	N-term	RWS	[45]
DK	c.552-560del	p.G184-G188del	Deletion	Exon_04	N-term	RWS	This study
	c.1096C > T	p.R366X	Nonsense	Exon_05	N-term	RWS	[4,8]
DK	c.1199T > A	p.I400N	Missense	Exon_06	N-term	RWS	[8]
	c.1283C > T	p.S428L	Missense	Exon_06	S1-S2	RWS	[38]
DK	c.1286delC	p.S428fs	Frameshift	Exon_06	S1-S2	RWS	[46]
DK	c.1591-1671del	p.R531-L539del	Deletion	Exon_07	S4-S5	RWS	This study
	c.1682C > T	p.A561V	Missense	Exon_07	S5	RWS	[4,19,25,47]
DK	c.1714G > C	p.G572R	Missense	Exon_07	S5-pore	RWS	[48]
	c.1750G > A	p.G584S	Missense	Exon_07	Pore	RWS	[25,45]
	c.1862G > A	p.S621N	Missense	Exon_07	Pore	RWS	[8,49,50]
	c.1886A > G	p.N629S	Missense	Exon_07	Pore	RWS	[4,51]
	c.1898A > G	p.N633S	Missense	Exon_07	Pore-S6	RWS	[51]
DK	c.2111_2114dup	p.W705fs	Frameshift	Exon_08	C-term	RWS	This study
DK	c.2573T > C	p.I858T	Missense	Exon_10	C-term	RWS	This study
	c.2738C > T	p.A913V	Missense	Exon_12	C-term	RWS	[4,16]
	c.2768delC	p.P923fs	Frameshift	Exon_12	C-term	RWS	[52]
DK	c.3090-3102del	p.S1029fs	Frameshift	Exon_13	C-term	RWS	This study

DK: Only seen in patients of Danish origin. **in vitro* functional characterization performed. RWS: Romano-Ward syndrome.

these must be expected to result in haploinsufficiency due to mRNA surveillance mechanisms. Of the remaining missense mutations, four had been electrophysiologically characterized *in vitro*, i.e. p.V254M [21], p.L273I [21,27,28], p.Y315C [43] and p.R583C [42]. Thus, only four out of 15 LQTS-associated missense mutations (27%) had established electrophysiological characteristics at the molecular level.

***KCNH2* mutations**

Twenty-eight mutations were identified in *KCNH2*. Fourteen of these were located in the N-terminus, and five of these were located in the Per-Arnt-Sim domain. Five were located in the C-terminus, only five mutations were located in the pore-region (Table 2). This is surprising, as the majority of previously identified LQTS associated

mutations in *KCNH2* have been located in the pore region [2]. Fifteen of the mutations have only been described in the Danish population. Eight of the Danish specific mutations were deletions, or frameshift mutations. The remaining eight Danish-specific mutations were missense mutations and all involved conserved amino acid residues. Among the mutations found in other populations, two were frameshift mutations, one was nonsense and 10 were missense mutations. Only one of these missense mutations, p.F29L, had been demonstrated to have an *in vitro* electrophysiological effect compatible with LQTS [43], so the remainder were considered disease-associated based on the evolutionary conservation of the involved amino acid residue and the absence of the mutation among 364 control alleles as well as a previously reported association with LQTS. The observation of the association of these

Table 3 Mutations identified in *SCN5A*, *KCNE1* or *KCNE2*

Gene	cDNA	Protein	Mutation type	Genomic region	Protein region	Phenotype	References
<i>SCN5A</i>	NM_000335	NP_000326					
DK	c.611+1G > A	Intronic splice	Splice-site	IVS5	D1-S3	RWS	This study
DK	c.955C > A	p.G319S	Missense	Exon_08	D1-S5-S6	RWS	[7]
	c.1018C > T	p.R340W	Missense	Exon_09	D1-S5-S6	RWS	[4]
DK	c.1141-3C > A	Intronic splice	Splice-site	IVS9	D1-S6	RWS	This study
	c.1231G > A	p.V411M	Missense	Exon_10	D1-S6	RWS	[4,16]
	c.4783T > A	p.F1595I	Missense	Exon_27	DIV-S3	RWS	[4]
DK	c.4786G > A	p.V1596M	Missense	Exon_27	DIV-S3	RWS	This study
DK	c.5354T > A*	p.L1785Q	Missense	Exon_28	C-term	RWS	This study
	c.6013C > G*	p.P2005A	Missense	Exon_28	C-term	RWS	[53]
<i>KCNE1</i>	NM_000219	NP_000210					
DK	c.179G > A	p.G60D	Missense	Exon_03	TM	RWS	This study
	c.226G > A*	p.D76N	Missense	Exon_03	Cyto	RWS	[4,25,52,54-56]
DK	c.277G > A	p.A93T	Missense	Exon_03	Cyto	RWS	This study
<i>KCNE2</i>	NM_172201	NP_751951					
	c.170T > C*	p.I57T	Missense	Exon_02	TM	RWS	[4,57-61]
	c.193G > A*	p.V65M	Missense	Exon_02	TM	RWS	[59]

DK: Only seen in patients of Danish origin. **in vitro* functional characterization performed. RWS: Romano-Ward syndrome.

mutations with LQTS in the Danish population corroborates their role in the causation of LQTS. Finally, a large number of mutations in the regions affected by the mutations described here, have been associated with LQTS [2].

All the remaining missense mutations in *KCNH2*, except p.A913V, were conserved to the level of zebrafish. The p.A913V mutation changed an alanine into a valine, where the valine was found at the same codon in rodents. However, the mutation had previously been associated with LQTS [16] and in the absence of deviations from familial disease segregation, and the absence of other mutations in the five genes as well as of the mutation in 364 control alleles, it was considered disease-causing.

***SCN5A* mutations**

Nine mutations were identified in *SCN5A* (Table 3), five of which have only been described in the Danish population. Four mutations have not been reported before. Two mutations were intronic splice-site mutations and the remaining mutations were missense mutations located in the DI, DIV and C-terminal regions. This distribution is compatible with the one found when accumulating all known *SCN5A* LQTS-associated mutations [2]. The splice-site mutations were considered disease-causing because they are believed to result in aberrant mRNA splicing resulting in the synthesis of *SCN5A* ion channels with prolonged depolarisation contributing to delayed repolarisation. The splice mutations most likely do not result in haploinsufficiency as this would most likely give a Brugada syndrome phenotype [63]. One of the missense

mutations, p.P2005A, has previously been associated with sudden infant death syndrome and shown to result in late persistent I_{Na} current, compatible with LQTS [53]. An *in vitro* electrophysiological analysis of the functional consequence of the p.L1785Q mutation has shown that it results in increased late persistent I_{Na} current, but also in a reduction of the total I_{Na} (Kanters et al., submitted), suggesting that the electrophysiological phenotype may be a combination of Brugada syndrome and LQTS, as previously described for *SCN5A* mutations [63], e.g. the p.E1784K mutation [64]. The remaining missense mutations interfere with conserved residues and have not been found in controls; further the mutations p.F1596I and p.V1597M, are located in the C-terminal part of *SCN5A*, where mutations causing LQTS are particularly frequent [2]. The rare polymorphism p.D1819N, known to be associated with increased QT-interval in normal individuals [65], was found in a single p.F29L family and not considered pathogenic, despite being previously reported as associated with LQTS [57]. The C-terminally located mutations are likely to interfere with fast inactivation of the I_{Na} current [66]. Likewise, the remaining missense mutations, p.G319S, p.R340W and p.V411M, are located in the DI-S5-S6 region, a region with a high frequency of LQTS-associated mutations [2].

***KCNE1* mutations**

Three mutations were found in *KCNE1*, two of which, p.G60D and p.A93T, have only been found in the Danish population and have not been reported before. The p.

A93T was found associated with p.R583G in *KCNQ1* in an isolated proband, where family data were not attainable. The p.G60D and p.D76N interfered with amino acid residues conserved in human, rat, mouse, cow and frog, whereas the alanine at residue 93 was only conserved in mouse, rat, cow and human. However, the N-terminus of frog minK is not conserved at all from amino acid residue 85 – 105 in the human sequence (corresponding to residue 80 – 95 in the frog minK sequence). However, the missense mutations p.Y81C, p.W87R, p.R98W, and p.P127T – as well as p.D76N, located in the cytoplasmic C-terminus of minK, have previously been associated with LQTS [2].

KCNE2 mutations

Two mutations were found, p.I57T and p.V65M, both previously described in other populations as associated with LQTS [57,58] and shown to interfere with Kv7.1 function [59] in a way compatible with an association with LQTS. Both interfered with highly conserved residues and were not found in 384 control alleles.

Disease causation

The association between a mutation and disease is of paramount importance when the mutation findings are used for cascade screening and clinical management as is the case in Denmark [12]. This is a particular problem when family data are not sufficient to establish linkage. As none of the mutations are present in the 364 control alleles and all but three (*SCN5A*:p.P2005A, *KCNE1*:p.D76N and *KCNE2*:p.I57T) were absent from the EVS, moreover, the three variants reported here occurred at frequencies < 1:1000, it is therefore unlikely that the variants reported here are polymorphisms. Frame-shift, splice-site- nonsense- or indel mutations represents 31.2% of the mutations identified in this cohort (Tables 1, 2, 3). Such mutations have a direct effect on the integrity of the polypeptide chain and are considered explanatory for LQTS. However, the remaining 68.8% are missense mutations, that need to be differentiated from the naturally occurring functionally insignificant non-synonymous variants in the same proteins. A classical method of supporting disease causality in LQTS is electrophysiological examination of mutated channel proteins to disclose a reduction in repolarising K⁺- current (*KCNQ1*, *KCNH2*, *KCNE1*, *KCNE2*) or late persistence of depolarising Na⁺- current (*SCN5A*) [2]. Such information, however, was only available for 22.7% of the missense mutations (Tables 1, 2, 3).

We used the prediction servers Polyphen-2, SIFT and Mutation Assessor to assess the significance of all the missense mutations for interference with protein function. The results are given in Table 4. As expected the majority of mutations where an electrophysiological assessment was available (p.V254M, p.L273F, p.Y315C, p.R583C in

KCNQ1, p.F29L in *KCNH2*, p.L1785Q in *SCN5A*, p.D76N in *KCNE1*, p.I57T and p.V65M in *KCNE2*) were found to have an effect on protein function. One mutation, p.P2005A in *SCN5A* was not found to be disruptive of protein function, despite having been determined to cause functional impairment by *in vitro* electrophysiological assessment. This suggests that the sensitivity of these prediction servers is reasonable. The remaining, not functionally characterised, missense mutations, with the exception of *KCNQ1* - p.P73T, p.R583G, p.R583H; *KCNH2*:p.A913V and *KCNE1*:p.A93T, were all found to be at least possibly disruptive of protein function.

The founder mutations in KCNH2

Two of the missense mutations, p.F29L [43] and p.K101E [44], were found in five and two “unrelated” families, respectively. Haplotype analysis, using six polymorphic microsatellite markers, spanning 24.6 cM, flanking the *KCNH2* gene at distances ranging from 10.1 Mb 3’ to 2.9 Mb 5’ as shown in Figure 1, demonstrated that both mutations were founder mutations (Additional file 1: Table S1).

Population distribution of mutations

The distribution of Danish LQTS mutations is compared with four other large mutation surveys comprising verified LQTS patients in Table 5. The proportion of *KCNQ1* mutations seems to be lower in Danish patients, 34.3%, than in other populations, where the proportion of *KCNQ1* mutations ranged from 39.4% - 48.6%. This trend was not significant, however, using a Chi-Square test. The proportion of *KCNH2* mutations in Denmark is within the range seen in the other populations, whereas the proportion of patients with mutations in the three rarely affected genes, *SCN5A*, *KCNE1* and *KCNE2* is considerably higher, 23.7%, than seen in the other populations (range: 10.7% - 16.2%). The distribution of mutation types does not seem to differ substantially between the populations. Likewise, the frequency of compound heterozygosity was similar in the populations where it was established. In a Norwegian study no compound heterozygotes were convincingly demonstrated, but 18 cases of Jervell and Lange-Nielsen syndrome had been found [67].

Discussion

We have identified 64 different mutations in 70 Danish LQTS families referred for five-gene screening. This is by far the highest number of different mutations identified per capita in any country and it amounts to approximately 1: 72.000 inhabitants. The signature of the genetics of LQTS in Denmark is that of many “private” mutations (Tables 1, 2, 3). With respect to this considerable inter-allelic and inter-genic variation, the Danish mutation spectrum is similar to that found in other populations

Table 4 *In silico* functional analysis of missense variants

Gene	Protein	Polyphen-2	SIFT	Mutation assessor
<i>KCNQ1</i>	p.P73T	0	0	0
<i>KCNQ1</i>	p.F157C	0	1	2
<i>KCNQ1</i>	p.I198V	1	1	1
<i>KCNQ1</i>	p.S225L	1	1	1
<i>KCNQ1</i>	p.A226V	2	1	2
<i>KCNQ1</i>	p.V254M	2	1	2
<i>KCNQ1</i>	p.L273F	2	1	2
<i>KCNQ1</i>	p.A302V	2	1	2
<i>KCNQ1</i>	p.Y315C	2	1	3
<i>KCNQ1</i>	p.G350R	2	1	2
<i>KCNQ1</i>	p.H363N	1	1	2
<i>KCNQ1</i>	p.R366W	2	1	2
<i>KCNQ1</i>	p.R583C	1	0	1
<i>KCNQ1</i>	p.R583G	0	0	1
<i>KCNQ1</i>	p.R583H	0	0	1
<i>KCNH2</i>	p.F22S	2	0	2
<i>KCNH2</i>	p.F29L	0	1	2
<i>KCNH2</i>	p.T74M	2	1	2
<i>KCNH2</i>	p.I96T	1	1	2
<i>KCNH2</i>	p.K101E	0	1	3
<i>KCNH2</i>	p.L109P	1	0	2
<i>KCNH2</i>	p.R176W	2	1	0
<i>KCNH2</i>	p.I400N	2	1	2
<i>KCNH2</i>	p.S428L	0	0	2
<i>KCNH2</i>	p.A561V	2	1	2
<i>KCNH2</i>	p.G572R	2	1	2
<i>KCNH2</i>	p.G584S	1	0	0
<i>KCNH2</i>	p.S621N	1	1	3
<i>KCNH2</i>	p.N629S	2	1	2
<i>KCNH2</i>	p.N633S	1	0	1
<i>KCNH2</i>	p.I858T	1	1	2
<i>KCNH2</i>	p.A913V	0	0	0
<i>SCN5A</i>	p.G319S	0	0	2
<i>SCN5A</i>	p.R340W	1	1	0
<i>SCN5A</i>	p.V411M	2	1	3
<i>SCN5A</i>	p.F1595I	0	0	2
<i>SCN5A</i>	p.V1596M	1	1	2
<i>SCN5A</i>	p.L1785Q	2	1	3
<i>SCN5A</i>	p.P2005A	0	0	0
<i>KCNE1</i>	p.G60D	2	1	2
<i>KCNE1</i>	p.D76N	1	0	2

Table 4 *In silico* functional analysis of missense variants (Continued)

<i>KCNE1</i>	p.A93T	0	0	1
<i>KCNE2</i>	p.I57T	2	1	1
<i>KCNE2</i>	p.V65M	2	1	1

Polyphen-2 scores: 0: benign, 1 possibly damaging for function; 2: Probably damaging for function. SIFT scores: 0: Tolerated and 1: Not tolerated, Mutation Assessor scores; 0-1: no functional effect, 2-3: functional effect on protein function.

(Table 5). However, there was a trend, albeit not significant, that the proportion of mutations in *KCNQ1* is reduced and the proportion of mutations in *SCN5A*, *KCNE1* and *KCNE2* correspondingly increased in the Danish LQTS patients. The same tendency is registered when comparing the Danish mutation spectrum to a collection of mutations identified in the five genes in persons referred for LQT testing, but where no knowledge on the clinical phenotype was available [4]. The relatively high frequency of mutations in the more rarely affected genes stresses the need of performing a five-gene screen when establishing the etiology of individual Danish LQTS families.

The patients described here were studied and collected over a long span of years, from 1996 – 2010. In this period the clinical picture of LQTS was better defined, the possibility of referral for genetic analysis increased and the indication for genetic analysis in LQTS cases was established in 2006 [6]. Furthermore, detailed clinical information was variable in quality, therefore it can not be excluded that, in some cases, other factors, e.g. structural heart disease or mixed phenotypes, might not have been identified and taken into account. Consequently, it is very difficult to establish a success rate for the genetic screening across this period. But it is probably comparable to the 70% reported from Norway in a much smaller collection of mutations [67]. Likewise, we cannot really state anything about the cost-effectiveness of including more genes in the basic screen or the suitability or cost-effectiveness of MLPA analysis of the five genes. A large proportion of cases, 65/70 had MLPA analysis performed in order to detect larger insertion/deletion mutations and a single case with a three exon deletion in *KCNQ1* was identified. However, considering the relatively low cost of MLPA analysis and the possibility to detect deletions that would have escaped classical Sanger sequencing, our data suggests that MLPA analysis – or more extensive methods for detection of minor structural abnormalities - should be part of the five gene screen as the frequency of deletions (1.4%) is comparable to that of KCNE mutations.

In general, disease causation was based on the identification of a mutation that; either resulted in a deletion or a frameshift, introduced a stop codon or disrupted correct splicing. In the case of missense mutations, the mutation should involve the exchange of a conserved amino

Table 5 Distribution of mutations and mutation types in this study and four other large studies

	This study	Berge et al [67]	Napolitano et al [38]	Tester et al [16]	Splawski et al [25]
Number of mutations	64	37	233	211	177
<i>KCNQ1</i> (%)	34.3	42.6	48.6	41.7	39.4
<i>KCNH2</i> (%)	43.8	46.3	38.8	42.2	51.5
<i>SCN5A</i> (%)	14.1	9.3	10.1	15.2	6.1
<i>KCNE1</i> (%)	4.7	1.9	1.7	0.5	2.3
<i>KCNE2</i> (%)	3.1	0.0	0.7	0.5	2.3
Mutation type					
Missense (%)	68.8	64.9	72.0	75.0	72.3
Nonsense (%)	3.1	13.5	5.1	5.7	6.2
Deletion (%)	9.4	2.7	14.1	2.5	5.0
Frameshift (%)	14.1	13.5	6.1	11.4	9.6
Splice site (%)	4.7	5.4	2.7	4.3	6.7
Compound heterozygotes (%)*	1.4	0	3.9	5.4	n.a.

*Percentage of families.

acid and not be present in >100 control alleles. If the mutation had previously been associated with LQTS this strengthened the argument for disease-causation. Functional assessment was not available for novel mutations. However, a large proportion, 48.4%, of mutations were classified as disease-causing as a consequence of the mutation type or the results of functional *in vitro* assessment. None of the mutations were present in Danish controls and three were found at very low frequencies in the EVS. The remaining missense mutations all, with five exceptions, were positive for disrupting protein function in one or several prediction servers. The prediction servers had a reasonable sensitivity, 9/10 functionally characterised mutations were correctly classified, but detailed analyses on larger datasets are necessary to establish specificity. Despite the promising performance of protein function interference prediction servers it will still be of great significance to be able to perform a functional analysis of identified novel variants.

Interestingly, this study and a subsequent survey of the cardiology clinics revealed that Andersen syndrome, despite being originally described in Denmark [68], as well as Jervell and Lange-Nielsen syndrome and Timothy syndrome patients, are not found in Danish cardiology clinics (Kanters, pers.com.).

The identification of a large *KCNH2* p.F29L founder family, comprising 7.1% of Danish LQTS families, is interesting, and the location of the family in the Northern part of Jutland, where it constitutes ca. 50% of affected families makes it easier to genotype patients from this part of Denmark. The p.F29L mutation has previously been found in North America [43] in a family of Northern European origin (Splawski, pers. com.). The mutation has been found to have an electrophysiological effect *in vitro* compatible with LQTS [43].

Each LQTS family has to be carefully examined as there is a risk of compound heterozygosity or digenic inheritance. Our data suggest that this risk is similar to that reported in other countries (Table 5). The clarification of the individual significance of either mutation in a family with a compound heterozygous index patient requires cascade screening to be performed and identification of carriers of the single mutations. In our experience this is rarely possible due to the small size of families [12].

The translation of molecular findings in LQTS patients into patient-specific clinical management decisions is difficult due to the low level of strict evidence, the complexity of the genetics, including the existence of genetic modifiers of phenotype [10]. Some of these problems may be alleviated if the use of patient-specific pluripotent stem cells turns out to give relevant information [69]. However, until such new approaches become routine, it is, with reference to the large role played by the use of previously reported information on disease-causation, important that all mutation findings and clinical as well as molecular follow-up of mutations are made available to the larger scientific community.

Conclusions

The Danish spectrum of LQTS causing mutations is very similar to that of the rest of the world, even though the frequency of *KCNQ1* mutations seems relatively reduced and the proportion of mutations in rarely affected genes increased. There was a considerable proportion of novel mutations identified, but they were distributed on the genes largely as seen elsewhere. Despite a shortage of functional information and a long collection period nearly all mutations identified were reasonably classified as causative. The identification of a large founder family with p.F29L in *KCNH2* may become of importance for local

patient management as well as studies into the prevention of sudden cardiac death in LQT2. Sharing of genotype and phenotype data as well as development of improved *in silico* predictions of functional consequences of mutations will improve the management of LQTS.

Additional file

Additional file 1: Table S1. Haplotyping of the p.K101E and p.F29L families.

Competing interest

The authors declare that they have no competing interests.

Authors' contributions

MC: participated in the design of the study, data acquisition, interpretation and drafting the manuscript; PLH: participated in data acquisition and data interpretation as well as critical revision of the manuscript; BS: participated in data acquisition, analysis and interpretation; JT: participated in data acquisition, analysis and interpretation as well as critical revision of the manuscript; TPL: participated in data acquisition, analysis and interpretation; OE: participated in data acquisition, analysis and interpretation; KMS: participated in data acquisition and analysis; ATH: participated in data acquisition, analysis and interpretation; LBO: participated in data acquisition, analysis and interpretation; LNP: participated in data acquisition, analysis and interpretation; RFS: participated in data acquisition, analysis and interpretation; FHA: participated in data acquisition and analysis; MGH: participated in data acquisition, analysis and interpretation; JH: participated in data acquisition, analysis and interpretation; *PEBT*: participated in data acquisition, analysis and interpretation; ET: participated in data acquisition, analysis and interpretation; *FLH*: participated in data acquisition, analysis and interpretation; *HB*: participated in data acquisition, analysis and interpretation; *HKJ*: participated in data acquisition, analysis and interpretation; *JJK*: participated in the design of the study, data acquisition and interpretation as well as critical revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

Dr. Igor Splawski, Novartis Institutes for Biomedical Research and Professor Mike Sanguinetti, University of Utah, are thanked for help with information the p.F29L mutation. The Danish Strategic Research Council is thanked for financial support.

Author details

¹Department of Clinical Biochemistry, Immunology and Genetics, Statens Serum Institut, Ørestads Boulevard 5, 2300S, Copenhagen, Denmark. ²US/MRC Centre for Molecular and Cellular Biology, Division of Molecular Biology and Human Genetics, Department of Biomedical Science, University of Stellenbosch, Cape Town, South Africa. ³The Heart Centre, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ⁴Department of Medical Genetics, University Hospital Rikshospitalet, Oslo, Norway. ⁵Department of Cardiology, Ålborg Hospital, Aalborg University, Ålborg, Denmark. ⁶Department of Clinical Biochemistry, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark. ⁷Department of Clinical Genetics, Odense University Hospital, Odense, Denmark. ⁸Department of Molecular Medicine, Aarhus University Hospital Skejby, Aarhus, Denmark. ⁹Department of Internal Medicine, Haderslev Hospital, Haderslev, Denmark. ¹⁰Department of Cardiology, Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark. ¹¹Center for Sensory-Motor Interaction, Aalborg University, Ålborg, Denmark. ¹²Department of Cardiology, Odense University Hospital, Odense, Denmark. ¹³Department of Cardiology, Aarhus University Hospital Skejby, Aarhus, Denmark. ¹⁴Institute of Biomedical Science, University of Copenhagen, Copenhagen, Denmark. ¹⁵Danish Arrhythmia Research Center (DARC), Copenhagen, Denmark.

Received: 4 October 2013 Accepted: 18 February 2014
Published: 7 March 2014

References

1. Crotti L, Celano G, Dagradi F, Schwartz PJ: **Congenital long QT syndrome.** *Orphanet J Rare Dis* 2008, **3**:18.
2. Hedley PL, Jorgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M: **The genetic basis of long QT and short QT syndromes: a mutation update.** *Hum Mutat* 2009, **30**(11):1486–1511.
3. Yang Y, Liang B, Liu J, Li J, Grunnet M, Olesen SP, Rasmussen HB, Ellinor PT, Gao L, Lin X, Li L, Wang L, Xiao J, Liu Y, Liu Y, Zhang S, Liang D, Peng L, Jespersen T, Chen YH: **Identification of a Kir3.4 mutation in congenital long QT syndrome.** *Am J Hum Genet* 2010, **86**(6):872–880.
4. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD, Wilde AA, Ackerman MJ: **Spectrum and prevalence of mutations from the first 2,500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.** *Heart Rhythm* 2009, **6**(9):1297–1303.
5. Antzelevitch C: **Role of spatial dispersion of repolarization in inherited and acquired sudden cardiac death syndromes.** *Am J Physiol Heart Circ Physiol* 2007, **293**(4):H2024–2038.
6. DCS: **Arvelige hjertesydrome.** Volume 1. 1st edition. Copenhagen: KLS Grafisk Hus A/S; 2006.
7. Hofman-Bang J, Behr ER, Hedley P, Tfelt-Hansen J, Kanters JK, Haunsøe S, McKenna WJ, Christiansen M: **High-efficiency multiplex capillary electrophoresis single strand conformation polymorphism (multi-CE-SSCP) mutation screening of SCN5A: a rapid genetic approach to cardiac arrhythmia.** *Clin Genet* 2006, **69**(6):504–511.
8. Larsen LA, Andersen PS, Kanters J, Svendsen IH, Jacobsen JR, Vuust J, Wettrell G, Tranebjærg L, Bathen J, Christiansen M: **Screening for mutations and polymorphisms in the genes KCNH2 and KCNE2 encoding the cardiac HERG/MIRP1 ion channel: implications for acquired and congenital long Q-T syndrome.** *Clin Chem* 2001, **47**(8):1390–1395.
9. Larsen LA, Andersen PS, Kanters JK, Jacobsen JR, Vuust J, Christiansen M: **A single strand conformation polymorphism/heteroduplex (SSCP/HD) method for detection of mutations in 15 exons of the KVLQT1 gene, associated with long QT syndrome.** *Clin Chim Acta* 1999, **280**(1–2):113–125.
10. Møller DV, Pecini R, Gustafsson F, Hassager C, Hedley P, Jespersgaard C, Torp-Pedersen C, Christiansen M, Kober LV: **Hereditary hemochromatosis (HFE) genotypes in heart failure: relation to etiology and prognosis.** *BMC Med Genet* 2010, **11**:117.
11. Kapa S, Tester DJ, Salisbury BA, Harris-Kerr C, Pungliya MS, Alders M, Wilde AA, Ackerman MJ: **Genetic testing for long-QT syndrome: distinguishing pathogenic mutations from benign variants.** *Circulation* 2009, **120**(18):1752–1760.
12. Theilade J, Kanters J, Henriksen FL, Gillsa-Hansen M, Svendsen JH, Eschen O, Toft E, Reimers JI, Tybjaerg-Hansen A, Christiansen M, Jensen HK, Bundgaard H: **Cascade screening in families with inherited cardiac diseases driven by cardiologists: feasibility and nationwide outcome in long QT syndrome.** *Cardiology* 2013, **126**(2):131–137.
13. Adzhubei I, Jordan DM, Sunyaev SR: **Predicting functional effect of human missense mutations using PolyPhen-2.** *Curr Protoc Hum Genet* 2013, Chapter 7:Unit7 20.
14. Sim NL, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC: **SIFT web server: predicting effects of amino acid substitutions on proteins.** *Nucleic Acids Res* 2012, **40**(Web Server issue):W452–457.
15. Reva B, Antipin Y, Sander C: **Predicting the functional impact of protein mutations: application to cancer genomics.** *Nucleic Acids Res* 2011, **39**(17):e118.
16. Tester DJ, Will ML, Haglund CM, Ackerman MJ: **Compendium of cardiac channel mutations in 541 consecutive unrelated patients referred for long QT syndrome genetic testing.** *Heart Rhythm* 2005, **2**(5):507–517.
17. Larsen LA, Christiansen M, Vuust J, Andersen PS: **High-throughput single-strand conformation polymorphism analysis by automated capillary electrophoresis: robust multiplex analysis and pattern-based identification of allelic variants.** *Hum Mutat* 1999, **13**(4):318–327.
18. Liu W, Yang J, Hu D, Kang C, Li C, Zhang S, Li P, Chen Z, Qin X, Ying K, Li Y, Li Y, Li Z, Cheng X, Li L, Qi Y, Chen S, Wang Q: **KCNQ1 and KCNH2 mutations associated with long QT syndrome in a Chinese population.** *Hum Mutat* 2002, **20**(6):475–476.
19. Priori SG, Napolitano C, Schwartz PJ: **Low penetrance in the long-QT syndrome: clinical impact.** *Circulation* 1999, **99**(4):529–533.
20. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S,

- Miyamoto Y, Goldenberg I, Andrews ML, McNitt S: **Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene.** *Circulation* 2007, **115**(19):2481–2489.
21. Wang Q, Curran ME, Splawski I, Burn TC, Millholland JM, VanRaay TJ, Shen J, Timothy KW, Vincent GM, de Jager T, Schwartz PJ, Toubin JA, Moss AJ, Atkinson DL, Landes GM, Connors TD, Keating MT: **Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias.** *Nat Gen* 1996, **12**(1):17–23.
 22. Choi G, Kopplin LJ, Tester DJ, Will ML, Haglund CM, Ackerman MJ: **Spectrum and frequency of cardiac channel defects in swimming-triggered arrhythmia syndromes.** *Circulation* 2004, **110**(15):2119–2124.
 23. Donger C, Denjoy I, Berthet M, Neyroud N, Cruaud C, Bennaceur M, Chivoret G, Schwartz K, Coumel P, Guicheney P: **KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome.** *Circulation* 1997, **96**(9):2778–2781.
 24. Paulussen A, Matthijs G, Gewillig M, Verhasselt P, Cohen N, Aerssens J: **Mutation analysis in congenital Long QT Syndrome—a case with missense mutations in KCNQ1 and SCN5A.** *Gen Test* 2003, **7**(1):57–61.
 25. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT: **Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2.** *Circulation* 2000, **102**(10):1178–1185.
 26. Struijk JJ, Kanters JK, Andersen MP, Hardahl T, Graff C, Christiansen M, Toft E: **Classification of the long-QT syndrome based on discriminant analysis of T-wave morphology.** *Med Biol Eng Comput* 2006, **44**(7):543–549.
 27. Shalaby FY, Levesque PC, Yang WP, Little WA, Conder ML, Jenkins-West T, Blarun MA: **Dominant-negative KvlQT1 mutations underlie the LQT1 form of long QT syndrome.** *Circulation* 1997, **96**(6):1733–1736.
 28. Wilson AJ, Quinn KV, Graves FM, Bitner-Glindzic M, Tinker A: **Abnormal KCNQ1 trafficking influences disease pathogenesis in hereditary long QT syndromes (LQT1).** *Cardiovasc Res* 2005, **67**(3):476–486.
 29. Chen S, Zhang L, Bryant RM, Vincent GM, Flippin M, Lee JC, Brown E, Zimmerman F, Rozich R, Szafranski P, Oberti C, Sterba R, Marangi D, Tchou PJ, Chung MK, Wang Q: **KCNQ1 mutations in patients with a family history of lethal cardiac arrhythmias and sudden death.** *Clin Genet* 2003, **63**(4):273–282.
 30. Napolitano C, Schwartz PJ, Brown AM, Ronchetti E, Bianchi L, Pinnavaia A, Acquaro G, Priori SG: **Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias.** *J Cardiovasc Electrophysiol* 2000, **11**(6):691–696.
 31. Splawski I, Shen J, Timothy KW, Vincent GM, Lehmann MH, Keating MT: **Genomic structure of three long QT syndrome genes: KVLQT1, HERG, and KCNE1.** *Genomics* 1998, **51**(1):86–97.
 32. Ackerman MJ, Schroeder JJ, Berry R, Schaid DJ, Porter CJ, Michels W, Thibodeau SN: **A novel mutation in KVLQT1 is the molecular basis of inherited long QT syndrome in a near-drowning patient's family.** *Pediatr Res* 1998, **44**(2):148–153.
 33. Ackerman MJ, Porter CJ: **Identification of a family with inherited long QT syndrome after a pediatric near-drowning.** *Pediatrics* 1998, **101**(2):306–308.
 34. Itoh T, Tanaka T, Nagai R, Kikuchi K, Ogawa S, Okada S, Yamagata S, Yano K, Yazaki Y, Nakamura Y: **Genomic organization and mutational analysis of KVLQT1, a gene responsible for familial long QT syndrome.** *Hum Genet* 1998, **103**(3):290–294.
 35. Kanters JK, Larsen LA, Orholm M, Agner E, Andersen PS, Vuust J, Christiansen M: **Novel donor splice site mutation in the KVLQT1 gene is associated with long QT syndrome.** *J Cardiovasc Electrophysiol* 1998, **9**(6):620–624.
 36. Li H, Chen Q, Moss AJ, Robinson J, Goytia V, Perry JC, Vincent GM, Priori SG, Lehmann MH, Denfield SW, Duff D, Kaine S, Shimizu W, Schwartz PJ, Wang Q, Towbin JA: **New mutations in the KVLQT1 potassium channel that cause long-QT syndrome.** *Circulation* 1998, **97**(13):1264–1269.
 37. Murray A, Donger C, Fenske C, Spillman I, Richard P, Dong YB, Neyroud N, Chevalier P, Denjoy I, Carter N, Syrris P, Afzal AR, Patton MA, Guicheney P, Jeffery S: **Splicing mutations in KCNQ1: a mutation hot spot at codon 344 that produces in frame transcripts.** *Circulation* 1999, **100**(10):1077–1084.
 38. Napolitano C, Priori SG, Schwartz PJ, Bloise R, Ronchetti E, Nastoli J, Bottelli G, Cerrone M, Leonardi S: **Genetic testing in the long QT syndrome: development and validation of an efficient approach to genotyping in clinical practice.** *JAMA* 2005, **294**(23):2975–2980.
 39. Sherman J, Tester DJ, Ackerman MJ: **Targeted mutational analysis of ankyrin-B in 541 consecutive, unrelated patients referred for long QT syndrome genetic testing and 200 healthy subjects.** *Heart Rhythm* 2005, **2**(11):1218–1223.
 40. Huang L, Bitner-Glindzic M, Tranebjaerg L, Tinker A: **A spectrum of functional effects for disease causing mutations in the Jervell and Lange-Nielsen syndrome.** *Cardiovasc Res* 2001, **51**(4):670–680.
 41. Tyson J, Tranebjaerg L, McEntagart M, Larsen LA, Christiansen M, Whiteford ML, Bathen J, Aslaksen B, Sorland SJ, Lund O, Pembrey ME, Malcolm S, Bitner-Glindzic M: **Mutational spectrum in the cardioauditory syndrome of Jervell and Lange-Nielsen.** *Hum Genet* 2000, **107**(5):499–503.
 42. Yang P, Kanki H, Drolet B, Yang T, Wei J, Viswanathan PC, Hohnloser SH, Shimizu W, Schwartz PJ, Stanton M, Murray KT, Norris K, George AL Jr, Roden DM: **Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes.** *Circulation* 2002, **105**(16):1943–1948.
 43. Chen J, Zou A, Splawski I, Keating MT, Sanguinetti MC: **Long QT syndrome-associated mutations in the Per-Arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation.** *J Biol Chem* 1999, **274**(15):10113–10118.
 44. Christiansen M, Tonder N, Larsen LA, Andersen PS, Simonsen H, Oyen N, Kanters JK, Jacobsen JR, Fosdal I, Wettrell G, Kjeldsen K: **Mutations in the HERG K⁺ ion channel: a novel link between long QT syndrome and sudden infant death syndrome.** *Am J Cardiol* 2005, **95**(3):433–434.
 45. Swan H, Viitasalo M, Piippo K, Laitinen P, Kontula K, Toivonen L: **Sinus node function and ventricular repolarization during exercise stress test in long QT syndrome patients with KvlQT1 and HERG potassium channel defects.** *J Am Coll Cardiol* 1999, **34**(3):823–829.
 46. Kanters JK, Haarmark C, Vedel-Larsen E, Andersen MP, Graff C, Struijk JJ, Thomsen PE, Christiansen M, Jensen HK, Toft E: **T(peak)T(end) interval in long QT syndrome.** *J Electrocardiol* 2008, **41**(6):603–608.
 47. Tanaka T, Nagai R, Tomoike H, Takata S, Yano K, Yabuta K, Haneda N, Nakano O, Shibata A, Sawayama T, Kasai H, Yazaki Y, Nakamura Y: **Four novel KVLQT1 and four novel HERG mutations in familial long-QT syndrome.** *Circulation* 1997, **95**(3):565–567.
 48. Larsen LA, Svendsen IH, Jensen AM, Kanters JK, Andersen PS, Moller M, Sorensen SA, Sandoe E, Jacobsen JR, Vuust J, Christiansen M: **Long QT syndrome with a high mortality rate caused by a novel G572R missense mutation in KCNH2.** *Clin Genet* 2000, **57**(2):125–130.
 49. Lupoglazoff JM, Denjoy I, Berthet M, Neyroud N, Demay L, Richard P, Hainque B, Vaksman G, Klug D, Leenhardt A, Maillard G, Coumel P, Guicheney P: **Notched T waves on Holter recordings enhance detection of patients with LQT2 (HERG) mutations.** *Circulation* 2001, **103**(8):1095–1101.
 50. Lupoglazoff JM, Denjoy I, Villain E, Fressart V, Simon F, Bozio A, Berthet M, Benamar N, Hainque B, Guicheney P: **Long QT syndrome in neonates: conduction disorders associated with HERG mutations and sinus bradycardia with KCNQ1 mutations.** *J Am Coll Cardiol* 2004, **43**(5):826–830.
 51. Satler CA, Vesely MR, Duggal P, Ginsburg GS, Beggs AH: **Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome.** *Hum Genet* 1998, **102**(3):265–272.
 52. Lai LP, Su YN, Hsieh FJ, Chiang FT, Juang JM, Liu YB, Ho YL, Chen WJ, Yeh SJ, Wang CC, Ko YL, Wu TJ, Ueng KC, Lei MH, Tsao HM, Chen SA, Lin TK, Wu MH, Lo HM, Huang SK, Lin JL: **Denaturing high-performance liquid chromatography screening of the long QT syndrome-related cardiac sodium and potassium channel genes and identification of novel mutations and single nucleotide polymorphisms.** *J Hum Genet* 2005, **50**(9):490–496.
 53. Arnestad M, Crotti L, Rognum TO, Insolia R, Pedrazzini M, Ferrandi C, Vege A, Wang DW, Rhodes TE, George AL Jr, Schwartz PJ: **Prevalence of long-QT syndrome gene variants in sudden infant death syndrome.** *Circulation* 2007, **115**(3):361–367.
 54. Bianchi L, Shen Z, Dennis AT, Priori SG, Napolitano C, Ronchetti E, Bryskin R, Schwartz PJ, Brown AM: **Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome.** *Hum Mol Genet* 1999, **8**(8):1499–1507.
 55. Duggal P, Vesely MR, Wattanasirichaigoon D, Villafane J, Kaushik V, Beggs AH: **Mutation of the gene for IsK associated with both Jervell and Lange-Nielsen and Romano-Ward forms of Long-QT syndrome.** *Circulation* 1998, **97**(2):142–146.

56. Splawski I, Tristani-Firouzi M, Lehmann MH, Sanguinetti MC, Keating MT: **Mutations in the hminK gene cause long QT syndrome and suppress IKs function.** *Nat Genet* 1997, **17**(3):338–340.
57. Millat G, Chevalier P, Restier-Miron L, Da Costa A, Bouvagnet P, Kugener B, Fayol L, Gonzalez Armengod C, Oddou B, Chanavat V, Froidefond E, Perraudin R, Rousson R, Rodriguez-Lafresse C: **Spectrum of pathogenic mutations and associated polymorphisms in a cohort of 44 unrelated patients with long QT syndrome.** *Clin Genet* 2006, **70**(3):214–227.
58. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA: **MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia.** *Cell* 1999, **97**(2):175–187.
59. Isbrandt D, Friederich P, Solth A, Haverkamp W, Ebneith A, Borggreffe M, Funke H, Sauter K, Breithardt G, Pongs O, Schulze-Bahr E: **Identification and functional characterization of a novel KCNE2 (MiRP1) mutation that alters HERG channel kinetics.** *J Mol Med* 2002, **80**(8):524–532.
60. Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: **Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.** *J Mol Med* 2004, **82**(3):182–188.
61. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL Jr, Goldstein SA: **A common polymorphism associated with antibiotic-induced cardiac arrhythmia.** *Proc Natl Acad Sci U S A* 2000, **97**(19):10613–10618.
62. Akimitsu N: **Messenger RNA surveillance systems monitoring proper translation termination.** *J Biochem* 2008, **143**(1):1–8.
63. Hedley P, Jorgensen P, Schlamowitz S, Moolman-Smook J, Kanter J, Corfield V, Christiansen M: **The genetic basis of Brugada syndrome: a mutation update.** *Hum Mutat* 2009, **30**(9):1256–1266.
64. Makita N, Behr E, Shimizu W, Horie M, Sunami A, Crotti L, Schulze-Bahr E, Fukuhara S, Mochizuki N, Makiyama T, Itoh H, Christiansen M, McKeown P, Miyamoto K, Kamakura S, Tsutsui H, Schwartz PJ, George AL Jr, Roden DM: **The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome.** *J Clin Invest* 2008, **118**(6):2219–2229.
65. Gouas L, Nicaud V, Berthet M, Forhan A, Tiret L, Balkau B, Guicheney P: **Association of KCNQ1, KCNE1, KCNH2 and SCN5A polymorphisms with QTc interval length in a healthy population.** *Eur J Hum Genet* 2005, **13**(11):1213–1222.
66. Wang DW, Yazawa K, George AL Jr, Bennett PB: **Characterization of human cardiac Na⁺ channel mutations in the congenital long QT syndrome.** *Proc Natl Acad Sci U S A* 1996, **93**(23):13200–13205.
67. Berge KE, Haugaa KH, Fruh A, Anfinsen OG, Gjesdal K, Siem G, Oyen N, Greve G, Carlsson A, Rognum TO, Hallerud M, Kongsgård E, Amlie JP, Leren TP: **Molecular genetic analysis of long QT syndrome in Norway indicating a high prevalence of heterozygous mutation carriers.** *Scand J Clin Lab Invest* 2008, **68**(5):362–368.
68. Andersen ED, Krasilnikoff PA, Overvad H: **Intermittent muscular weakness, extrasystoles, and multiple developmental anomalies: a new syndrome?** *Acta Paediatr Scand* 1971, **60**(5):559–564.
69. Moretti A, Bellin M, Welling A, Jung CB, Lam JT, Bott-Flugel L, Dorn T, Goedel A, Hohnke C, Hofmann F, Seyfarth M, Sinnecker D, Schömig A, Laugwitz KL: **Patient-specific induced pluripotent stem-cell models for long-QT syndrome.** *N Engl J Med* 2010, **363**(15):1397–1409.

doi:10.1186/1471-2350-15-31

Cite this article as: Christiansen et al.: Mutations in Danish patients with long QT syndrome and the identification of a large founder family with p.F29L in *KCNH2*. *BMC Medical Genetics* 2014 **15**:31.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

